key: cord-0926568-0o2w08qf authors: Hatami, Parvaneh; Balighi, Kamran; Nicknam Asl, Hamed; Aryanian, Zeinab title: COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus date: 2021-12-01 journal: Dermatol Ther DOI: 10.1111/dth.15216 sha: 566293f2b7f49f777daeb7f56aa3d0b1a8a629df doc_id: 926568 cord_uid: 0o2w08qf SARS‐COV2 vaccines were approved without long‐term monitoring due to emergent situations. This has raised some issues about the timing and protocol of receiving vaccines in specific situations such as patients receiving immunomodulatory agents including rituximab, which is widely used for various disorders such as multiple sclerosis, pemphigus, and many rheumatologic disorders. We described two cases of pemphigus vulgaris (a new case and one with flare‐up) following vaccination with Astrazeneca in Iran and reviewed the existing data in this regard through searching on PubMed, Google Scholar, and Scopus. All of the relevant papers published until June 28, 2021, which we could access their full‐texts were included. We found some recommendations made by rheumatologists, neurologists, and dermatologists in regard to vaccination timing in this group of patients and tried to summarize them to provide a practical guide for clinicians. Clinicians should perform a careful, individualized risk–benefit assessment for their patients and consider a delay in rituximab administration after completion of COVID vaccination if there is not any considerable risk of disease relapse or organ failure. Moreover, choosing vaccines with potential of providing protection after single dose, especially in countries with limited access to vaccines may be a reasonable approach. Our first case was a 34-year-old man, otherwise healthy with a history of vaccination with Astrazeneca in late July and initiation of sore throat and gingivitis a few days after that. When he came to our outpatient clinic, some mucosal erosions on his tongue and buccal parts were noted (Figure 1 ). Histopathological evaluation and direct immunofluorescence study confirmed the diagnosis of PV for him and treatment was initiated with prednisolone 1 mg/kg and Azathioprine 150 mg/day. Our second case was a 61-year-old man with confirmed diagnosis of Immunotherapy has become one of the best treatment modalities for different disorders during the last decades 2-6 and RTX, a monoclonal antibody targeting CD20 on B lymphocytes, has recently shown a great promising effect in treating various disorders including PV. Since a B cell depletion occurs during RTX therapy, it is not surprising that a higher risk of SARS-Cov-2 infection in patients treated with RTX has been reported in some studies. 7, 8 However, the safety of RTX in the COVID era is still a controversial issue. In a review of two phase III trials of RTX, no increased susceptibility to respiratory infections including COVID-19 was reported in patients with pemphigus who received rituximab as their first-line treatment, 9 which was in line with Previous studies about the effect of RTX on immunological response following inactivated vaccines showed attenuated, yet meaningful response, 10 but there is not any similar study on live attenuated vaccines in the literature due to safety concerns of these vaccines in those receiving RTX. 11 In fact, impaired humoral and even cellular immunological response to some vaccines including influenza, pneumococcal polysaccharide, and tetanus toxoid vaccines was reported in patients receiving RTX. 12, 13 However, it seems that T cell responsiveness improves faster than humoral immunity 14 and also T-cell dependent recall response, unlike primary antigen exposure response, might preserve after rituximab treatment, 15 The possibility of diminished efficacy of COVID vaccines in patients treating with RTX is not the only concern among patients and clinicians. In fact, the safety of adenovirus-based vaccines has not been proved yet, especially in patients with autoimmune disorders such as MS or PV and there is some reports of disease flare-up following vaccination with Sputnik V. 20 In our short-time experience about probable COVID-19 vaccineassociated pemphigus flare-up in Iran, we noticed that non-adenovirus based vaccines such as Sinopharm, which was used for most of our patients, were relatively safe in this regard. It is worthy to note that some new cases of PV following COVID infection or its vaccines including those without adenovirus such as Pfizer were reported in literature 21-23 that makes it even more challenging to choose an appropriate approach to remedy this complex issue. On the other hand, immune suppression is among the COVID-19-related mortality risk factors. 24 Hence, the risk of severe COVID infection in this group of patients along with the attenuated efficacy of the COVID vaccine should be borne in mind when making decision about vaccination or using immunomodulatory agents during this pandemic. In fact, these uncertainties raised among various specialists including rheumatologists, neurologists, hematologists, and dermatologists, necessitates the preparedness of a comprehensive guideline in this regard. The ideal timing of vaccination is unknown. Some authors suggest that the influenza vaccine recommendations needed to be performed regarding COVID vaccines. Therefore, they recommend COVID vaccination at least 4 weeks before RTX infusion and 12-20 weeks after that (assuming a 6-month gap between RTX treatment courses). 11, 25 The American college of Rheumatology guideline for COVID vaccination also suggests a 4-week gap between RTX therapy and vaccination. 26 Regarding assessment of vaccine efficacy in patients receiving RTX, despite the CDC recommendation against routine serologic assessment following vaccination, it seems that regular assessment of neutralizing antibody level and also IFN γ IGRA, if possible, following vaccination of these patients could be a helpful guide to choose appropriate timing of revaccination after humoral immune reconstitution in case of attenuated immunological response or emergence of new virus variants which necessitates receiving new vaccines. In conclusion, clinicians should perform a careful, individualized riskbenefit assessment for their patients and consider a delay in RTX administration after completion of COVID vaccination if there is not any considerable risk of disease relapse or organ failure. Moreover, choosing vaccines with potential of providing protection after single dose, especially in countries with limited access to vaccines may be a reasonable approach. Moreover, we suggest to use of non-adenovirus-based vaccines in patients with autoimmune disorders such as PV to avoid possible relapsing of underlying disorder. Overall, we think that in areas with a serious situation due to Coronavirus outbreak, it is rational to choose our vaccination strategy based on vaccine and also laboratory tests accessibility; If vaccines are easily accessible, the patients could be vaccinated after 4 weeks of RTX infusion and then, the need to or timing for next booster doses could be determined after assessing neutralizing antibody level and/or IGRA. On the other hand, in areas with limited access to these tests and vaccines, using strict preventive measures including patient isolation and postponing the vaccination at least for 12 weeks after rituximab administration might be a reasonable protocol. Further studies are needed to find an optimal time frame of vaccination and find out if there is a need for booster doses in patients under treatment with RTX. All the authors declare that there is no conflict of interest. Any aspect of the work that has involved human patients has been conducted obtaining the ethical approval of all relevant bodies. The data supporting the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0002-3531-2907 Kamran Balighi https://orcid.org/0000-0002-8059-670X Zeinab Aryanian https://orcid.org/0000-0001-7077-1458 COVID-19 in children: current evidence and key questions Randomized trial of tacrolimus 0.1% ointment versus triamcinolone acetonide 0.1% paste in the treatment of oral pemphigus vulgaris Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: a retrospective study A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata A prospective comparative study of two regimens of diphenylcyclopropenone (DPCP) in the treatment of alopecia areata Influence of narrow-band ultra violet B phototherapy on homocysteine status: a prospective study of patients with different cutaneous disorders Persisting SARS-CoV-2 viremia after rituximab therapy: two cases with fatal outcome and a review of the literature Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia Estimating the susceptibility to SARS-CoV-2 infection with rituximab use for pemphigus vulgaris COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases Immunizations in immunocompromised patients: a guide for dermatologists Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses B cell depletion impairs vaccination-induced CD8 + T cell responses in a type I interferondependent manner Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases COVID-19 and the risk of relapse in multiple sclerosis patients: a fight with no bystander effect? The SARS-CoV-2 as an instrumental trigger of autoimmunity Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2 Pemphigus vulgaris after COVID-19: a case of induced autoimmunity Treatment considerations for patients with pemphigus during the COVID-19 pandemic COVID-19 and ANCAassociated vasculitis -recommendations for vaccine preparedness and the use of rituximab American College of Rheumatology Guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version. Arthritis Rheumatol COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus